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Abstract  28 
Purpose Tobacco and alcohol use during pregnancy are serious public health concerns and result 29 
in adverse developmental outcomes. Identifying in utero exposure is often achieved through 30 
meconium analysis or via maternal self-report. In this study, we analyzed fetal liver and placenta 31 
to examine second trimester alcohol and smoking exposure. 32 
Methods A validated liquid chromatography-tandem mass spectrometry method for simultaneous 33 
analysis of nicotine and its metabolites and alcohol markers (ethyl glucuronide: EtG and ethyl 34 
sulfate: EtS) was employed to analyze 193 fetal liver and 48 placenta (n=47 paired) samples 35 
from electively-terminated pregnancies.  36 
Results EtG, EtS and nicotine markers’ limits of detection were 0.7-20 ng/g in fetal samples. 37 
Ninety-eight fetal liver and 23 placenta samples were EtG/EtS-positive, while 137 liver and 25 38 
placenta samples were positive for tobacco exposure. When both alcohol markers were present in 39 
samples, EtG/EtS ratios were 1.6-11.1 in 17 livers and 2.5-31.1 in 10 placentas. Median [range] 40 
summed tobacco marker concentrations were 422 [1.0-2776] and 154 [1.6-1621] ng/g in livers 41 
and placentas. Median EtG and nicotine marker concentrations were higher in liver than placenta 42 
in paired samples. Strong evidence of exposure occurred in 11 and 22 pairs, respectively, when 43 
both samples were positive for alcohol and/or tobacco markers.  44 
Conclusions These paired fetal liver and placenta alcohol and tobacco data provided a unique 45 
means for examining the effects of in utero exposure, a critical first step in selecting fetal 46 
samples for proteomic and RNA-sequencing studies that could provide mechanisms for adverse 47 
developmental outcomes. 48 
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Introduction 51 
Tobacco and alcohol use during pregnancy are serious public health concerns, resulting in 52 
adverse obstetrical and neonatal outcomes including miscarriage, preeclampsia, low birth weight, 53 
preterm delivery, fetal growth restriction, decreased head circumference, placenta abruption, and 54 
facial abnormalities [1-4]. Fetal alcohol spectrum disorders (FASD) encompass growth 55 
retardation, cognitive impairments, and craniofacial dysmorphology associated with prenatal 56 
alcohol exposure [5-6]. Prenatal tobacco exposure also can have a profound impact on infant 57 
brain structure and function, infant irritability, and risk for child behavioral and attention 58 
disorders [7-8]. Despite these documented health risks, in the 2015 US National Survey of Drug 59 
Use and Health (NSDUH), 13.9% of pregnant respondents reported current tobacco use and 60 
9.3% current alcohol use [9].  61 
Identifying prenatal alcohol and tobacco exposure is often achieved through meconium 62 
drug quantification and/or maternal self-reported drug use during pregnancy. Meconium is a 63 
good matrix for in utero drug exposure assessment in pregnancies carried to term. Although 64 
meconium formation begins as early as 13 weeks, other methods must assess earlier exposure. In 65 
this study, we examined whether analysis of fetal liver and placenta from electively-terminated 66 
pregnancies could determine exposure patterns during the second trimester.   67 
In adults, nicotine is oxidized to cotinine and trans-3’-hydroxycotinine (OHCOT) 68 
primarily by CYP2A13 and CYP2A6 [10], with additional phase II conjugation to nicotine-N-69 
glucuronide (Nic-G), cotinine-N-glucuronide (Cot-G), and OHCOT-O-glucuronide (OHCOT-G) 70 
[10]. Nicotine and these 5 metabolites account for 73-96% of the nicotine dose excreted in adult 71 
smokers’ urine [10]. Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are chemical markers 72 
indicating ethanol ingestion with longer detection times than ethanol. UDP-73 
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glucuronosyltransferase catalyzes ethanol conjugation with glucuronic acid to form EtG [11], 74 
while sulfotransferases conjugate ethanol and activated sulfate to form EtS [12]. Fetal liver and 75 
placental EtG is likely of maternal origin as EtG readily crosses the placenta and fetal 76 
glucuronidation capacity is limited [13-14]. Little is known about placental EtS transfer; 77 
however, fetal liver and placental EtS concentrations may result from maternal and/or fetal 78 
contributions, as variable yet significant fetal sulfotransferase activity was observed [15-16]. 79 
Fetal liver and placental EtG and EtS levels were investigated previously in a small cohort with 80 
few positives [17], while there are no available data on human fetal liver nicotine and its 81 
metabolites’ concentrations. 82 
Adult health is partly programmed during fetal development [18-21]. Gestational 83 
exposure to tobacco, alcohol, and other drugs alters normal hormone regulation early in fetal 84 
development [22-23]. Mechanisms through which fetal drug exposures result in reduced adult 85 
health are poorly understood. We present a validated analytical method for quantifying EtG/EtS 86 
and nicotine markers in fetal liver and placenta samples and describe how this method assessed 87 
in utero alcohol and tobacco exposure in fetuses from electively-terminated pregnancies. The 88 
goal was to select the most appropriate fetal samples to conduct fetal endocrine disruption and 89 
DNA/RNA damage assessments.  90 
 91 
Materials and methods 92 
Tissue samples 93 
The drug- and alcohol-negative matrix for human fetal liver analyses was a frozen calf liver. 94 
Human placentas from healthy pregnancies were donated by volunteers and the Johns Hopkins 95 
Bayview Medical Center Pathology Department. Blank matrices were confirmed negative at our 96 
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limits of quantification (LOQ) prior to calibrator and quality control (QC) preparation. Samples 97 
(193 fetal livers and 48 placentas including 47 paired samples) obtained from women who 98 
voluntarily terminated their pregnancies were analyzed. Fetus collection in Aberdeen was 99 
approved by the NHS Grampian Research Ethics Committees (REC 04/S0802/21). Women 100 
seeking elective terminations of pregnancy were recruited with full written, informed consent by 101 
nurses working independently of the study at Aberdeen Pregnancy Counseling Service. Maternal 102 
data, medications used, and self-reported number of cigarettes smoked per day were recorded. 103 
Only fetuses from normally-progressing pregnancies (determined by ultrasound scan), from 104 
women >16 years old and between 8-20 weeks of gestation, were collected following termination 105 
as detailed previously [24]. Fetuses were transported to the laboratory within 30 min of delivery, 106 
weighed, crown-rump length recorded, and sexed. Collection of human fetal liver and placenta 107 
pairs occurred at the University of Newcastle upon Tyne (England) through the Human 108 
Developmental Biology Resource at the Institute of Human Genetics under an Institutional 109 
Review Board-approved study. 110 
 111 
Reagents 112 
S(-)-Nicotine, (±)-nicotine-d4, (-)-cotinine, (±)-cotinine-d3, (R,S)-norcotinine, EtG, EtG-d5, EtS, 113 
and EtS-d5 were purchased from Cerilliant Corporation (Round Rock, TX, USA); nicotine-N-β-114 
D-glucuronide, cotinine-N-β-D-glucuronide, cotinine-d3-N-β-D-glucuronide, OHCOT, OHCOT-115 
d3, OHCOT-O-β-D-glucuronide, and (S)-cotinine-N-oxide as powders from Toronto Research 116 
Chemicals Inc. (Toronto, Canada); LCMS grade methanol, ammonium acetate, formic acid, 117 
HPLC grade acetonitrile, dichloromethane, isopropanol, ACS grade hydrochloric acid and 118 
ammonium hydroxide from Fisher Scientific (Fair Lawn, NJ, USA); fritted filters (10 µm, 15 119 
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mL) from United Chemical Technologies Inc. (Bristol, PA, USA); Isolute supported liquid 120 
extraction (SLE) columns (1 mg/6 mL) and Evolute-AX anion exchange solid-phase extraction 121 
(SPE) cartridges (100 mg/3 mL) from Biotage (Charlotte, NC, USA). 122 
 123 
Instrumentation 124 
Tobacco and alcohol markers were quantified on a SCIEX 5500 Qtrap® mass spectrometer with 125 
a TurboV electrospray ionization (ESI) source (SCIEX, Foster City, CA, USA), connected to a 126 
Shimadzu UFLCXR system with two LC-20ADXR pumps, a CTO-20 AC column oven, and a 127 
SIL-20ACXR autosampler (Shimadzu Corporation, Columbia, MD, USA). Data were acquired 128 
and processed with Analyst 1.5.1 (SCIEX). A Mini-BeadBeater-8 (BioSpec Products, 129 
Bartlesville, OK, USA) pulverized tissue. A CEREX-48 positive-pressure manifold was utilized 130 
for SPE (SPEware Corporation, Baldwin Park, CA, USA). Evaporation under nitrogen was 131 
conducted in a TurboVap LV evaporator (Zymark, Hopkinton, MA). 132 
 133 
Standard Solution Preparation 134 
Individual methanolic standard solutions were diluted to 100 mg/L in methanol. Powdered 135 
standards were reconstituted in the manufacturer’s recommended solvent and diluted to 100 136 
mg/L in methanol, except for OHCOT, which was maintained at 1 g/L. Methanolic dilutions 137 
yielded mixed working calibrator solutions of 0.01, 0.02, 0.05, 0.1, 0.25, 0.5, 1.5 and 3 mg/L for 138 
cotinine, and 2.5, 5, 10 and 20 times more concentrated for Nic-G, OHCOT; nicotine, EtS, Cot-139 
G; OHCOT-G; and EtG, respectively. QC solutions were prepared from different stocks than 140 
calibrators. Low, medium, and high QCs were prepared across the linear dynamic range for each 141 
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analyte. A mixed working internal standard methanolic stock was prepared at 0.1 (cotinine-d3), 142 
0.25 (EtS-d5, OHCOT-d3, Nic-G-d3), 0.5 (nicotine-d4, Cot-G-d3), and 1 mg/L (EtG-d5).  143 
 144 
Procedures 145 
Blank liver or placenta (0.25 g) was fortified with 25 µL calibrator or QC solution or 25 µL 146 
methanol for authentic samples, and 25 µL internal standard solution was added. Six to eight 3.2-147 
mm chrome-steel beads were added to each sample, followed by 0.95 mL 0.01% formic acid in 148 
methanol and pulverized for 2 s. The methanol was filtered and collected in polypropylene tubes. 149 
The original samples were rinsed with an additional 1 mL 0.01% formic acid in methanol, 150 
vigorously vortexed for 1 min, and filtered into the same tubes. Two 450-µL aliquots were 151 
transferred to separate tubes for SLE of nicotine and its metabolites and for anion-exchange SPE 152 
of EtG and EtS.  153 
For nicotine and metabolite extraction, 525 µL 0.25% ammonium hydroxide in methanol 154 
was added to the nicotine aliquot yielding pH >10. Samples were vortexed and poured onto 1 mL 155 
SLE beds. After 5 min equilibration, analytes were eluted with 2 x 2.5 mL 95:5 156 
dichloromethane/isopropanol into glass centrifuge tubes. Positive pressure was gradually applied 157 
up to 2.4 L/min to complete elution. A 50-µL volume of 1% HCl in methanol was added to the 158 
eluents before evaporation under nitrogen at 35°C. Reconstitution occurred in 200 µL of 10 mM 159 
ammonium acetate in water with 5 µL methanol added to aid pellet formation. Samples were 160 
vortexed and centrifuged at 1800g at 4°C for 5 min. A 150-µL volume was transferred to a 161 
microcentrifuge tube and centrifuged at 20,800g for 5 min at 4°C. A 125-µL volume was 162 
transferred to autosampler vials and 5 µL injected. For EtG and EtS extraction, 2 mL acetonitrile 163 
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and 10 µL 236 mM ammonium hydroxide were added to the 450 µL tissue supernatant, and the 164 
SPE followed our published meconium assay for these markers [25].  165 
 166 
Liquid chromatography-tandem mass spectrometry 167 
Nicotine and its metabolites were chromatographically separated on a Poroshell 120 EC-C8 168 
column (150 x 2.1 mm i.d., 2.7 µm particle size), fitted with a matching guard column (Agilent 169 
Technologies, Santa Clara, CA, USA) similarly to a previous publication [26]. Mobile phases A 170 
and B were 10 mM ammonium acetate in water and methanol, respectively. At 0.3 mL/min flow, 171 
the gradient started at 0% B, increased to 60% B over 6 min, increased to 100% B in 0.1 min, 172 
held at 100% B for 2.4 min, decreased to 0% B in 0.1 min, and held for 2.9 min; total run time 173 
was 11.5 min. Liquid chromatograph (LC) eluent was diverted to waste for the first min and the 174 
final 5.5 min.  175 
Mass spectrometric data for nicotine and metabolites were acquired via positive ESI. 176 
Compound-specific tandem mass spectrometry (MS/MS) parameters were optimized by infusing 177 
10 µg/L reference solutions at 10 µL/min dissolved in A/B (50:50, v/v) mobile phase (Table S1). 178 
Optimized source parameters were gas 1 60 psi, gas 2 40 psi, curtain gas 45 psi, source 179 
temperature 700°C, and ion spray voltage 5500 V. Three periods were utilized to acquire 180 
multiple reaction monitoring (MRM) mode data with period 1 (2.5 min, 100 ms dwell) consisting 181 
of Cot-G and Cot-G-d3; period 2 (1.7 min, 50 ms dwell) Nic-G, OHCOT-G, and Nic-G-d3; and 182 
period 3 (7.3 min, 30 ms dwell) OHCOT, cotinine, nicotine, OHCOT-d3, cotinine-d3, and 183 
nicotine-d4. Additional MRMs for two isobaric compounds were not quantified; cotinine-N-184 
oxide (m/z 193.0>96.0, 193.0>78.8) and norcotinine (m/z 163.0>80.0, 163.0>118.1) were only 185 
monitored in periods 2 and 3, respectively.  186 
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LC and MS parameters for EtG and EtS were adapted from our previously published 187 
meconium method [25]. However, the quantifying EtG transition, m/z 221>75, was replaced by 188 
m/z 221>85m/z, due to matrix interferences at low concentrations (Table S1).  189 
 190 
Validation 191 
Sensitivity, linearity, specificity, accuracy, imprecision, extraction efficiency, matrix effect, 192 
dilution integrity, carryover, and stability were evaluated according to Scientific Working Group 193 
for Forensic Toxicology (SWGTOX) guidelines [27] as summarized in Table S2.  194 
 195 
Results  196 
This method is the first to offer simultaneous extraction of EtG, EtS, nicotine, cotinine, OHCOT, 197 
and 3 prominent nicotine glucuronide metabolites from a human fetal liver or placenta sample. 198 
Although initial tissue extraction was simultaneous, marked physiochemical differences between 199 
acidic EtG and EtS and basic nicotine and metabolites required different SPE and LC 200 
approaches.  201 
Limits of detection (LODs), LOQs, linear ranges, and calibration curves for both matrices 202 
are presented in Table 1. Accuracy and imprecision results for liver and placenta are presented in 203 
Table 2. Extraction recoveries and matrix effects for liver and placenta are given in Table 3. 204 
Stability results for all conditions and all samples are summarized in Table 4. All validation 205 
experiments met acceptability criteria (Table S2). 206 
The validated methods were used for the analysis of 193 fetal livers and 48 placentas (47 207 
paired) samples. Summarized concentration data for all analytes and matrices are found in Table 208 
5. When both alcohol markers were present in a sample (17 livers and 10 placenta samples), an 209 
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EtG/EtS ratio was calculated and ranged from 1.6-11.1 in liver and 2.5-31.1 in placenta. The six 210 
tobacco marker concentrations in each individual sample were summed. Median [range] 211 
summation concentrations were 422 [1.0-2776] and 154 [1.6-1621] ng/g in liver and placenta, 212 
respectively.  213 
We identified in utero alcohol and tobacco exposures based on EtG/EtS and nicotine 214 
marker concentrations in liver and placenta. Currently, there are not sufficient pre-existing fetal 215 
data in the literature to guide interpretation. Our criteria for determining evidence of alcohol and 216 
tobacco exposure are described in Table 6, based on presence of and concentrations of multiple 217 
analytes. For each matrix, numbers of samples in each predicted exposure category are also 218 
tabulated. Results from this study are utilized for selecting fetuses for later DNA and RNA 219 
analyses that will examine exposure and possible damage at the genomic level.   220 
When both alcohol markers were detected together, EtG concentrations were 27.0-2050 221 
ng/g and 34.3-1168 ng/g, and EtS concentrations were 7.3-423 ng/g and 7.9-214 ng/g in 17 fetal 222 
livers and 10 placentas, respectively. Only one fetal liver had detectable EtG (31.9 ng/g) without 223 
EtS with no paired placenta for comparison, while 6 placenta samples were positive for EtG only 224 
(35.1-628 ng/g). EtS was often detected alone in 81/193 fetal liver (5.1-42.0 ng/g) and 7/48 225 
placenta (6.9-35.6 ng/g) samples. Median EtG concentrations were higher in liver than placenta 226 
(Table 5). Of the 11 paired samples indicating strong evidence of recent alcohol exposure, 3 227 
pairs contained both markers in both matrices, while 3 pairs were negative in liver but positive 228 
for EtG and EtS in placenta. Overall, 95/193 fetal liver and 25/48 placenta samples, including 21 229 
paired samples, were negative for EtG and EtS (Table 6). 230 
One or more nicotine markers were detected in 137/193 liver and 25/48 placenta samples. 231 
Median nicotine and metabolite concentrations were higher in liver than in placenta, including 232 
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median concentration sums (Table 5). Low tobacco marker concentrations or presence of few 233 
analytes were difficult to interpret and were classified as weak or moderate evidence of recent 234 
exposure, but did not preclude previous maternal use if there was a period of abstinence prior to 235 
pregnancy termination. Summed nicotine marker concentrations weakly indicative of recent 236 
tobacco exposure were 1.0-13.0 ng/g and 1.6-10.8 ng/g in fetal liver and placenta, respectively, 237 
while moderate evidence encompassed summed concentrations of 8.3-421 ng/g and 43.7-154 238 
ng/g in fetal liver and placenta, respectively. When strong evidence of tobacco exposure was 239 
predicted, summed concentrations were 290-2776 ng/g and 148-1621 ng/g in fetal liver and 240 
placenta, respectively (Table 5). Of the paired samples, 6 indicated strong evidence of both 241 
alcohol and tobacco exposure. No tobacco analytes were detected above the LOQ in 56/193 fetal 242 
livers and 23/48 placentas, including 20 paired samples (Table 6). 243 
 244 
Discussion 245 
This novel, comprehensive method was fully validated according to SWGTOX guidelines [27] 246 
for EtG, EtS, nicotine and phase I and phase II metabolites in a fetal liver or placenta sample. 247 
The methodology was successfully applied to the analysis of 193 fetal liver and 48 placenta 248 
samples from electively terminated pregnancies for the determination of in utero exposure to 249 
alcohol and tobacco.  250 
 Our investigation is only the second to look at fetal liver and placental EtG and EtS. A 251 
previous study by Morini et al. [17] tested 35 matched liver-placenta pairs from women who 252 
terminated their pregnancy at week 12. In this previous study, four fetal livers were EtG-positive 253 
(33-391 ng/g) with three also positive for EtS (15-51 ng/g). In placenta, four were EtG- (122-254 
1307 ng/g) and EtS- (10-126 ng/g) positive and were paired with the four fetal livers with 255 
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detectable EtG. Two additional placenta samples were positive only for EtS (29 and 175 ng/g). 256 
EtG/EtS ratios in the three dual positive liver samples were 3.9, 5.3, and 7.3; while EtG/EtS 257 
ratios in the four dual positive placentas were 12.7, 12.7, 4.8, and 10.4. EtG and EtS were always 258 
higher in placenta compared to those of liver [17]. Our EtS LOQ is the same as that of Morini et 259 
al. (5 ng/g) [17], but our EtG LOQ was 20 ng/g. We fully homogenized the 250 mg liver by 260 
bead-beating, enabling a more efficient and reproducible release of drugs as compared to an 261 
acetonitrile wash reported by them, but produced additional matrix effects, requiring us to raise 262 
our LOQ. However, our LOQ was below the concentrations in all samples identified and 263 
reported by them. 264 
 In order to select samples for further testing, we examined alcohol and tobacco markers 265 
in fetal, infant, and adult studies. EtG readily crosses the placenta [20]; therefore, fetal liver EtG 266 
is likely to be primarily of maternal origin, as fetal glucuronidation capacity is limited [13]. No 267 
placental diffusion EtS studies exist. However, fetal liver sulfotransferases showed variable yet 268 
significant activities [15]. It is possible that the fetal liver EtS is of fetal origin, or of both the 269 
fetal and maternal origin. 270 
 When considering adult alcohol markers, if EtG and EtS are present, there is a strong 271 
indication of alcohol ingestion [28]. EtG and EtS are only produced by antemortem drinking, 272 
enabling differentiation of postmortem ethanol formation from antemortem drinking. EtG was 273 
reported to occasionally degrade in postmortem samples [28-29], suggesting superiority of EtS 274 
analysis. In addition, EtS is not formed in the presence of putrefaction or with lack of 275 
preservatives [28,30]. For our fetal samples, presence of EtS or EtG only as well as that of both 276 
compounds can be considered alcohol-exposed. 277 
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 In meconium, we previously reported that COT, NIC, or OHCOT concentrations ≥10 278 
ng/g suggested active maternal tobacco exposure during pregnancy [31], although subsequent 279 
work by our group found lower cutoffs, equivalent to analytical LOQs (1 ng/g COT, 2.5 ng/g 280 
NIC, and 5 ng/g OHCOT), and better identified active maternal smoking [3]. This suggests that 281 
detecting any marker in meconium indicates maternal smoking during pregnancy, and 282 
environmental or passive exposure would produce undetectable tobacco marker concentrations in 283 
meconium. In serum, COT ≤3 ng/mL differentiated passive from active maternal exposure 284 
[10,31]. In support of our previous 10 ng/g cutoff, Braun et al. [32] showed that in infants of 285 
tobacco-smoking mothers with a mean serum COT >3 ng/mL, the lower limit of the 95% 286 
confidence interval for meconium COT was 10 ng/g. Additionally, among these infants with 287 
exposure to maternal active tobacco smoking, multiple meconium tobacco markers were detected 288 
[31]. For our fetal samples, presence of multiple markers, especially above the median, was 289 
considered the criteria for tobacco-exposed. 290 
 To our knowledge, these are the first fetal liver tobacco marker concentrations, although 291 
there are other placenta and fetal human brain concentration data. The transfer rate for nicotine 292 
across the placenta was about 90% [33]. In 12th week-terminated pregnancies, evidence of fetal 293 
tobacco exposure was observed, with placenta median (range) COT and NIC concentrations of 294 
80 (25-190) ng/g and 61 (33-120) ng/g, respectively [34]. In a single human postmortem fetal 295 
brain sample, 40 ng/g COT, 65 ng/g OHCOT, and no NIC were detected [35], although the 296 
timing of tobacco exposure was unavailable. In adult postmortem liver, COT was always higher 297 
(4-25 times) than NIC and both analytes were detected at higher concentrations than in blood; 298 
COT and NIC concentrations in adult liver were 260-1586 ng/g and 14-325 ng/g, respectively 299 
[36].  300 
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 We predicted alcohol and tobacco exposure based on analyte presence and their 301 
concentrations, although there are few data to guide interpretation. It is important to publish 302 
quantitative data for future investigations. Molecular analyses in prenatal alcohol and tobacco-303 
exposed fetuses may eventually suggest mechanisms for adverse fetal outcomes and perhaps 304 
correlations between fetal liver or placenta concentrations and outcomes. Relevantly, a balanced 305 
population of the 80 fetal livers and the 145 Aberdeen fetal livers that we report here is currently 306 
being analyzed by shotgun proteomics and RNA-sequencing. No recent alcohol exposure was 307 
demonstrated by absence of EtG and EtS, as absence of these markers may only indicate 308 
maternal abstinence for a few days prior to termination. It is possible that these samples could 309 
provide a wider window of alcohol or tobacco detection, but we have no data on timing or 310 
magnitude of exposure. The fetal liver EtG detection window following acute or chronic 311 
maternal alcohol consumption is unknown, although EtG and EtS are detected in adult urine for 312 
40-130 h after the end of drinking in most cases [37-38].  313 
 Fetuses exhibiting strong evidence of recent alcohol exposure were selected primarily 314 
from samples positive for both EtG and EtS (n = 17 for liver, n = 10 for placenta), with an 315 
additional 2 placenta identified when EtG concentration ≥ median concentration. Moderate 316 
evidence of recent alcohol exposure identified 45 liver and 4 placenta samples with EtS detected 317 
≥ median concentration despite no detectable EtG. Given potential EtG instability and higher 318 
EtG LOQ, EtS-only positive cases could indicate exposure. In addition, differential metabolic 319 
pathway rates in mothers or fetuses could result in more EtS than EtG as EtS is stable [28], and 320 
there are no published cases of artificial EtS formation. However, in adults, urine EtS detection 321 
could occur after extreme non-traditional drinking behaviors, including non-alcoholic beer [39], 322 
sauerkraut [39], ripened bananas [39], grape juice [39], and non-alcoholic wine [29]. In the 323 
15 
 
present study, three placentas were EtG and EtS positive, although paired liver samples were 324 
negative. Additionally, three liver samples were positive for EtS-only (8.6, 9.9, and 17.0 ng/g) 325 
with no analytes detected in placenta, while nine EtS-only placenta (6.9-35.6 ng/g) samples had 326 
paired liver samples negative for both alcohol markers. Therefore, alcohol exposure was 327 
suggested in this study, but cannot be definitively determined.  328 
 No recent tobacco exposure was identified in fetal liver and placenta samples that were 329 
negative for all six tobacco markers. Tobacco marker absence may indicate recent maternal 330 
abstinence but not necessarily throughout pregnancy. Detection windows for tobacco markers in 331 
fetal liver and placenta are unknown. In cases where only a few markers were detected, 332 
interpretation was difficult and low concentrations could possibly be attributed to minimal 333 
maternal smoking, abstinence for a few days prior to termination or passive maternal tobacco 334 
smoke exposure. Large population sampling studies showed positive, but low, mean serum 335 
cotinine concentrations among self-reported nonsmokers and passively exposed individuals [10]. 336 
For this reason, samples positive for 5/6 or 6/6 analytes with high summed concentrations were 337 
considered to exhibit strong evidence of recent tobacco exposure, especially due to the presence 338 
of phase I and phase II nicotine metabolites. 339 
 340 
Conclusions 341 
While timing of gestational alcohol or tobacco use is unknown, we were able to identify 342 
multiple, specific alcohol and tobacco markers for selecting samples for proteomic and RNA-343 
sequencing studies. Our validated analytical method successfully quantified alcohol (EtG and 344 
EtS) and tobacco markers (nicotine and phase I and phase II metabolites) and sought to predict 345 
alcohol and tobacco exposure. After consulting the literature for fetal studies and examining 346 
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analyte concentrations in other matrices, we stratified our fetal liver and placenta data to 347 
categorize strength of evidence of recent maternal alcohol or tobacco consumption, exposing 348 
pre-term fetuses to potentially harmful chemicals at a young gestational age. For the first time, a 349 
large cohort of paired, exposed fetal liver and placenta samples were analyzed. Publishing these 350 
data is crucial to inform future research, as this is the first comprehensive analysis of paired fetal 351 
liver and placenta samples for evidence of in utero alcohol and tobacco exposure.  352 
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Table 1 Linearity, and limit of detection (LOD) and limit of quantification (LOQ) results 
SD standard deviation, OHCOT trans-3’-hydroxycotinine 
  
Analyte LOD (ng/g) 
LOQ 
(ng/g) 
Linear range                    
(ng/g)  
Liver Placenta 
y-Intercept               
(mean±SD, n=5) 
Slope             
(mean±SD, n=5) 
R2                
(range, n=5) 
y-Intercept       
(mean±SD, n=5) 
Slope             
(mean±SD, n=5) 
R2              
(range, n=5) 
Cotinine-N-glucuronide 5 5 5-1500 0.011 ± 0.065 1.223 ± 0.128 0.997 - 0.999 -0.024 ± 0.018 1.252 ± 0.054 0.993 - 0.999 
Nicotine-N-glucuronide 1.75 2.5 2.5-750 -0.025 ± 0.005 0.812 ± 0.060 0.993 - 0.998 -0.029 ± 0.004 0.832 ± 0.025 0.994 - 0.998 
OHCOT-O-glucuronide 7 10 10-1500 0.000 ± 0.000 0.017 ± 0.001 0.995 - 1.000 -0.001 ± 0.001 0.034 ± 0.007 0.992 - 1.000 
OHCOT 1.75 2.5 2.5-750 -0.005 ± 0.011 1.172 ± 0.027 0.997 - 0.999 -0.003 ± 0.006 1.134 ± 0.018 0.998 - 0.999 
Cotinine  0.7 1 1-300 0.040 ± 0.019 0.982 ± 0.039 0.993 - 0.998 0.054 ± 0.016 1.007 ± 0.065 0.996 - 0.999 
Nicotine  3.5 5 5-1500 0.066 ± 0.044 1.058 ± 0.024 0.995 - 0.998 0.085 ± 0.047 1.172 ± 0.218 0.993 - 0.998 
Ethyl sulfate (EtS) 5 5 5-1500 0.014 ± 0.031 1.200 ± 0.010 0.997 - 0.999 0.000 ± 0.000 1.100 ± 0.032 0.996 - 0.999 
Ethyl glucuronide (EtG) 20 20 20-3000 -0.050 ± 0.111 7.182 ± 0.270 0.989 - 0.998 0.000 ± 0.000 5.036 ± 0.282 0.996 - 1.000 
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Table 2 Accuracy (bias) and imprecision results for tobacco and alcohol markers in fetal liver and placenta samples 
 Analyte Concentration (ng/g) 
Liver Placenta 
Mean 
between-
run bias 
(%, n=20) 
Within-run bias 
range 
(%, n=5) 
Between-run 
imprecision 
(%CV, n=20) 
Maximum-within 
run imprecision 
(%CV, n=5) 
Mean 
between-
run bias 
(%, n=20) 
Within-run bias 
range 
(%, n=5) 
Between-run 
imprecision 
(%CV, n=20) 
Maximum-within 
run imprecision 
(%CV, n=5) 
Cotinine-N-glucuronide 15 99.1 88.7 - 109 5.2 9.9 96.6 84.0 - 117 11.9 13.2 
  300 104 91.7 - 114 5.4 6.1 102 91.7 - 113 5.7 5.9 
  1200 101 90.8 - 114 5.5 5.9 108 92.5 - 116 5.6 7.8 
Nicotine-N-glucuronide 7.5 106 94.8 - 113 4.2 4.6 99.7 94.5 - 112 4.5 5.9 
  150 97.6 87.3 - 112 6.6 6.7 94.9 84.7 - 108 5.4 9.1 
  600 92.4 84.5 - 103 6.9 6.7 99.5 87.2 - 112 7.5 7.4 
OHCOT-O-glucuronide 30 106 94.0 - 115 5.8 6.4 105 89.0 - 119 8.5 6.9 
  600 104 92.3 - 115 6.7 7.8 104 92.3 - 119 8.6 10.6 
  1200 108 97.5 - 115 5.5 5.8 107 90.8 - 116 7.4 10.1 
OHCOT 7.5 110 102 - 115 3.3 6.0 113 105 - 117 2.4 4.7 
  150 110 106 - 115 2.4 3.5 113 103 - 117 3.6 6.9 
  600 107 94.5 - 115 4.7 4.0 110 99.7 - 115 3.6 6.0 
Cotinine  3 102 92.3 - 113 5.9 7.1 106 97.7 - 114 4.1 3.5 
  60 104 94.8 - 113 5.3 6.6 107 92.2 - 115 5.0 8.6 
  240 95.5 87.9 - 113 8.3 7.7 94.9 85.0 - 107 6.2 8.2 
Nicotine  15 107 88.7 - 115 6.9 12.1 107 90.7 - 117 7.3 10.6 
  300 107 99.3 - 115 4.7 4.5 108 95.0 - 115 5.0 7.8 
  1200 111 99.2 - 115 3.5 4.9 108 80.7 - 116 10.6 13.0 
Ethyl sulfate (EtS) 15 105 95.3 - 115 5.9 5.8 108 98.7 - 117 4.7 6.9 
  300 103 95.7 - 115 5.0 4.7 107 92.3 - 116 5.2 8.3 
  1200 106 98.3 - 114 4.0 3.6 106 93.3 - 115 5.2 4.8 
Ethyl glucuronide (EtG) 60 98.3 86.8 - 113 8.6 10.4 98.4 85.3 - 107 4.7 8.5 
  1200 93.9 84.2 - 107 8.8 10.3 97.5 85.0 - 108 7.3 8.2 
  2400 105 87.9 - 115 8.4 9.6 110 90.8 - 118 5.6 8.8 
CV coefficient of variation  
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Table 3 Extraction efficiencies and matrix effects for tobacco and alcohol markers in liver and placenta samples 
Analyte 
Liver Placenta 
Extraction efficiency 
(%, n=5) 
Matrix effect 
(%, n=5) 
Extraction efficiency 
(%, n=5) 
Matrix effect 
(%, n=5) 
Lowa Highb Low High Low High Low High 
Cotinine-N-glucuronide 54.4 53.0 12.3 11.0 31.6 31.3 -16.6 -32.4 
Nicotine-N-glucuronide 64.4 70.5 -40.0 -25.2 48.8 56.6 -2.5 -16.3 
OHCOT-O-glucuronide 60.4 57.9 -57.3 -50.3 55.9 60.9 -15.6 -35.1 
OHCOT 92.6 93.6 -44.3 -32.4 88.5 93.9 -11.2 -20.8 
Cotinine 92.3 92.2 -42.2 -32.8 107 103 -22.7 -23.9 
Nicotine 90.9 80.3 -33.2 -33.3 82.8 92.2 8.0 -21.3 
Ethyl sulfate (EtS) 76.1 71.9 -30.6 -17.5 73.1 68.1 -24.5 -10.5 
Ethyl glucuronide (EtG) 86.8 86.0 -50.6 -51.4 94.1 91.5 -27.3 -24.5 
Cot-G-d3 49.2 45.8 17.3 14.8 27.6 32.4 -10.0 -27.1 
Nic-G-d3 57.9 59.7 -38.2 -25.7 51.4 58.2 -4.4 -8.3 
OHCOT-d3 85.7 82.7 -43.4 -28.6 91.3 89.7 -18.2 -14.2 
Cotinine-d3 89.1 83.6 -45.7 -32.1 102 101 -35.8 -23.7 
Nicotine-d4 80.4 73.9 -42.5 -27.9 93.4 92.1 -18.8 -16.3 
EtS-d5 63.4 72.6 -34.9 -35.9 68.0 74.0 -28.6 -38.3 
EtG-d5 78.1 96.5 -44.1 -50.5 88.3 97.1 0.2 -11.4 
Cot-G cotinine-N-glucuronide, Nic-G nicotine-N-glucuronide 
aLow quality control concentrations were 3 ng/g cotinine, 7.5 ng/g nicotine-N-glucuronide and OHCOT, 15 ng/g nicotine, cotinine-N-
glucuronide, and EtS, 30 ng/g OHCOT-O-glucuronide and 60 ng/g EtG 
bHigh quality control concentrations were 240 ng/g cotinine, 600 ng/g nicotine-N-glucuronide and OHCOT, 1200 ng/g nicotine, 
cotinine-N-glucuronide, EtS and OHCOT-O-glucuronide, and 4800 ng/g EtG 
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Table 4 Stability results (%, n = 4) of fortified liver and placenta samples in various storage conditions prior to and following extraction  
Analyte 
12h Room temperature 72h 4°C 3 Freeze/thaw cycles 72h Autosampler (4°C) 5 Days supernatantc (4°C) 
Lowa Highb Low High Low High Low High Low High 
Liver 
Cotinine-N-glucuronide 84.4 83.3 87.6 101 96.9 96.7 98.8 99.6 96.4 92.6 
Nicotine-N-glucuronide 86.1 83.0 95.8 93.8 89.2 84.6 97.4 85.6 90.8 81.4 
OHCOT-O-glucuronide 89.1 101 109 117 94.4 111 111 106 108 104 
OHCOT 114 109 110 116 110 110 111 101 107 94.3 
Cotinine 112 115 113 108 113 98.5 104 94.9 98.6 85.6 
Nicotine 110 113 112 113 115 108 112 99.3 104 92.3 
Ethyl sulfate (EtS) 106 103 101 105 103 105 102 111 104 107 
Ethyl glucuronide (EtG) 91.1 106 98.1 99.7 102 104 97.0 109 95.2 98.2 
Placenta 
Cotinine-N-glucuronide 106 108 91.3 99.1 101 107 88.3 116 98.7 113 
Nicotine-N-glucuronide 97.3 103 91.8 87.0 103 90.6 97.4 104 98.5 93.2 
OHCOT-O-glucuronide 115 116 96.3 92.2 99.5 96.0 109 114 97.0 112 
OHCOT 115 108 110 102 116 111 115 112 115 111 
Cotinine 88.3 81.7 110 96.2 111 98.4 108 101 104 94.7 
Nicotine 81.9 86.4 111 106 109 112 99.1 90.4 109 117 
Ethyl sulfate (EtS) 107 97.3 99.9 103 103 113 108 104 107 113 
Ethyl glucuronide (EtG) 96.5 104 92.6 95.1 101 113 113 116 102 113 
aLow quality control concentrations were 3 ng/g cotinine, 7.5 ng/g nicotine-N-glucuronide and OHCOT, 15 ng/g nicotine, cotinine-N-
glucuronide, and EtS, 30 ng/g OHCOT-O-glucuronide and 60 ng/g EtG 
bHigh quality control concentrations were 240 ng/g cotinine, 600 ng/g nicotine-N-glucuronide and OHCOT, 1200 ng/g nicotine, 
cotinine-N-glucuronide, EtS and OHCOT-O-glucuronide, and 4800 ng/g EtG 
cAcidified, methanolic tissue supernatant resulting from filtration, prior to extraction 
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Table 5 Summary concentration data for alcohol and nicotine markers in fetal liver (n=193) and placenta (n=48) among positive samples, including minimum, 
mean, median, and maximum concentrations (ng/g).  
  EtG EtS EtG/EtS 
ratio 
CotG NicG OHCotG OHCOT COT NIC Individual summations 
of tobacco markers   LOQ (ng/g) 20 5 5 2.5 10 2.5 1 5 
Liver (n=193) Total positive (n) 18 97 17 111 117 51 113 136 105 137 
 Minimum positive (ng/g) 27.0 5.1 1.6 5.2 2.9 10.0 2.5 1.0 5.1 1.0 
 Mean (ng/g) 303 26.7 3.9 192 74.3 25.2 82.0 279 25.1 592 
 Median (ng/g) 122 13.0 3.5 153 54.0 16.0 70.0 126 22.5 422 
 Maximum (ng/g) 2050 423 11.1 745 437 375 313 1332 108 2776 
Placenta (n=48) Total positive (n) 16 17 10 20 18 10 22 24 22 25 
 Minimum positive (ng/g) 34.3 6.9 2.5 6.4 2.8 15.1 4.4 1.6 5.5 1.6 
 Mean (ng/g) 253 36.6 8.7 80.4 42.2 44.7 97.9 67.6 45.6 304 
 Median (ng/g) 86.0 17.0 6.7 21.6 5.5 28.7 59.5 48.8 22.7 154 
 Maximum (ng/g) 1168 214 31.1 455 467 118 455 221 460 1621 
Ratio of EtG to EtS is presented for samples with both analytes present. Summations of tobacco markers were also calculated for 
individual samples. 
CotG cotinine-N-glucuronide, NicG nicotine-N-glucuronide, OHCotG hydroxycotinine-N-glucuronide, COT cotinine, NIC nicotine
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Table 6 Summary of criteria used to stratify evidence of alcohol and tobacco exposure for fetal liver and placenta and number of samples in each category of 
predicted exposure 
 Liver 
(n = 193) 
Placenta 
(n = 48) 
Liver & placenta pairs 
(n = 47) 
Alcohol 
No evidence Weak evidence 
Moderate 
evidence 
Strong 
evidence No evidence 
Weak 
evidence 
Moderate 
evidence 
Strong 
evidence No evidence 
Weak 
evidence 
Strong 
evidence 
EtG & EtS 
not detected 
> LOQ 
EtG or EtS       
< median 
concentration 
Absence of 
EtG, + EtS  ≥ 
median 
concentration 
EtG & EtS 
detected      
> LOQ; or 
EtG ≥ 
median 
EtG & EtS 
not detected 
> LOQ 
EtG or EtS       
< median 
concentration 
Absence of 
EtG, + EtS    
≥ median 
concentration 
EtG & EtS 
detected > 
LOQ; or EtG 
≥ median 
Both 
matrices 
negative for 
EtG & EtS 
One matrix 
positive for 
EtG or EtS 
Either 
matrix 
positive for 
EtG & EtS; 
or both 
matrices 
positive for 
EtG or EtS 
n = 95 n = 36 n = 45 n = 17 n =25 n = 7 n = 4 n = 12 n = 21 n = 15 n = 11 
Tobacco 
No evidence Weak evidence 
Moderate 
evidence 
Strong 
evidence No evidence 
Weak 
evidence 
Moderate 
evidence 
Strong 
evidence No evidence 
Weak 
evidence 
Strong 
evidence 
No analytes 
detected  
> LOQ 
1-2 Analytes 
present  
< median 
concentration 
≥ 3 Analytes 
detected but 
sum  
< median 
All analytes 
detected; or 
5 analytes 
with sum  
> median 
No analytes 
detected  
> LOQ 
1-2 Analytes 
present  
< median 
concentration 
≥ 3 Analytes 
detected but 
sum  
< median 
All analytes 
detected; or 
5 analytes 
with sum  
> median 
Both 
matrices 
negative for 
all analytes 
1-2 Analytes 
present in 
liver +/or 
placenta 
≥ 3 Analytes 
in both 
matrices; or 
moderate & 
strong 
evidence 
between the 
two matrices 
n = 56 n = 23 n = 44 n = 70 n = 23 n = 4 n = 9 n = 12 n = 20 n = 5 n = 22 
 
 
